BiofarmBSE:BIO -0.73%69 OCF Margin % is 43.42% as of Mar. 2026, which is 73% above its 10-year median of 25.10. GuruFocus rates BSE:BIO with a GF Score™ of 69/100 and a GF Value™ of lei0.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 963 Drug Manufacturers companies, Biofarm ranks better than 92.32% on this metric.
The historical rank and industry rank for Biofarm's OCF Margin % or its related term are showing as below:
BSE:BIO'
s OCF Margin % Range Over the Past 10 Years
Min: 10.48 Med: 25.1 Max: 37.35
Current: 29.21
During the past 13 years, the highest OCF Margin % of Biofarm was 37.35%. The lowest was 10.48%. And the median was 25.10%.
BSE:BIO's OCF Margin % is ranked better than 92.32% of 963
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs BSE:BIO: 29.21
Biofarm OCF Margin % Related Terms
Biofarm OCF Margin % Historical Data
* Premium members only.
The historical data trend for Biofarm's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:BIO vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Biofarm's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofarm (BSE:BIO) has a OCF Margin % of 43.42% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biofarm and its competitors. This is 73% above median its historical median of 25.10. Over the past decade, Biofarm's OCF Margin % has ranged from 10.48 to 37.35. According to the industry distribution chart, Biofarm ranks #74 out of 963 companies in the Drug Manufacturers industry, placing it in the top 7.7%.
Is Biofarm's OCF Margin % too high?
Biofarm's current OCF Margin % of 43.42% is 73% above median its 10-year median of 25.10. Over the past 10 years, this metric has ranged from a low of 10.48 to a high of 37.35. The Drug Manufacturers industry median OCF Margin % is 9.95. Biofarm's value of 43.42% is 336.4% above this industry median. Based on the distribution chart, Biofarm ranks #74 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofarm has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #74 out of 963 companies for OCF Margin %. This places Biofarm in the top 8% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Biofarm's value of 43.42% is 336.4% above this benchmark. Historically, Biofarm's own OCF Margin % has ranged from 10.48 to 37.35 over the past decade. While the company's 10-year median is 25.10 vs. the industry median of 9.95, Biofarm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current OCF Margin % of 43.42% is 336.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current OCF Margin % is 43.42%, which is 73% above median its own 10-year median of 25.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.87, compared to a current price of lei1.36 — trading 56.3% above its estimated fair value. The current OCF Margin % is 43.42%, which is 73% above median its 10-year median of 25.10 and 336.4% above the Drug Manufacturers industry median of 9.95. Biofarm's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current OCF Margin % is 43.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (BSE:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei1.36 is trading 56.3% above its estimated GF Value™ of lei0.87.
GuruFocus considers Biofarm to be Significantly Overvalued.
Key valuation signals for BSE:BIO:
OCF Margin %: 43.42% (73% above median its 10-year median of 25.10)
GF Value™: lei0.87 vs. price of lei1.36 (56.3% above fair value)
Industry Position: 336.4% above the Drug Manufacturers median (#74 of 963)
No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score
Get the complete analysis for BSE:BIO
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:BIO has been successfully added to your 
